Alexander M Eggermont

Alexander M Eggermont

UNVERIFIED PROFILE

Are you Alexander M Eggermont?   Register this Author

Register author
Alexander M Eggermont

Alexander M Eggermont

Publications by authors named "Alexander M Eggermont"

Are you Alexander M Eggermont?   Register this Author

100Publications

11094Reads

32Profile Views

The impact of the immunotherapy revolution on lymph nodal surgery.

Bull Cancer 2019 Oct 11. Epub 2019 Oct 11.

University Paris-Sud, Gustave Roussy Cancer Campus Grand Paris, 114, rue Edouard-Vaillant, 94800 Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2019.05.013DOI Listing
October 2019

The new era of adjuvant therapies for melanoma.

Nat Rev Clin Oncol 2018 09;15(9):535-536

Department of Medicine, Division of Hematology and Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41571-018-0048-5
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0048-5DOI Listing
September 2018

Adjuvant Pembrolizumab in Resected Stage III Melanoma.

N Engl J Med 2018 08;379(6):593-595

European Organization for the Research and Treatment of Cancer Headquarters, Brussels, Belgium

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1807505DOI Listing
August 2018

Reply to 'Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma'.

Nat Commun 2018 07 26;9(1):2922. Epub 2018 Jul 26.

Institut de Cancérologie Gustave Roussy Cancer Campus (GRCC), 114 rue Edouard Vaillant, 94805, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-05048-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062500PMC
July 2018

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

N Engl J Med 2018 May 15;378(19):1789-1801. Epub 2018 Apr 15.

From the Gustave Roussy Cancer Campus Grand Paris and University Paris-Saclay, Villejuif (A.M.M.E., C.R.), Hospices Civils de Lyon Cancer Institute, Cancer Research Center of Lyon, Lyon University, Lyon (S.D.), and Aix-Marseille University, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille (J.-J.G.) - all in France; Netherlands Cancer Institute-Antoni van Leeuwenhoek (C.U.B., A.C.J.A.) and VU University Medical Center (A.J.M.E.), Amsterdam, and Radboud University Medical Center Nijmegen, Nijmegen (R.K.) - all in the Netherlands; Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (M. Mandala), Istituto Nazionale Tumori Istituto di Ricovero e Cura a Carattere Scientifico Fondazione G. Pascale, Naples (P.A.A.), and Universita Degli Studi Di Siena-Policlinico le Scotte, Siena (M. Maio) - all in Italy; Melanoma Institute Australia, the University of Sydney, and Mater and Royal North Shore Hospitals (G.V.L.) and Westmead and Blacktown Hospitals, Melanoma Institute Australia and the University of Sydney (M.S.C.), Sydney, Princess Alexandra Hospital, University of Queensland, Brisbane (V.A.), Alfred Hospital (A.H.) and Peter MacCallum Cancer Centre (S. Sandhu), Melbourne, VIC, and Fiona Stanley Hospital-University of Western Australia-Edith Cowan University Perth, Perth (A.K.) - all in Australia; Cancer Research Center, Moscow (M.L.); Royal Marsden Hospital, London (J.L.); Hospital Clinic Universitari de Barcelona, Barcelona (S.P.); Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland (P.R.); University Hospital Essen, Essen and German Cancer Consortium, Heidelberg (D.S.), and the Skin Cancer Center, Department of Dermatology, Hannover Medical School, Hannover (R.G.) - all in Germany; Washington University School of Medicine, St. Louis (L.H.-A.); Centre Hospitalier de l'Université de Montréal (CHUM), Centre de Recherche du CHUM, Montreal (R.J.); Christie NHS Foundation Trust, Manchester, United Kingdom (P.L.); Merck, Kenilworth, NJ (N.I.); and the European Organization for the Research and Treatment of Cancer Headquarters, Brussels (S.M., S. Suciu).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1802357DOI Listing
May 2018

Combination Immunotherapy Development in Melanoma.

Am Soc Clin Oncol Educ Book 2018 May;38:197-207

From the Gustave Roussy Cancer Institute and University Paris-Saclay, Villejuif, France; Earle A. Chiles Research Institute, Portland, OR; The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201131DOI Listing
May 2018

Neoadjuvant therapy in melanoma: the next step?

Lancet Oncol 2018 02 18;19(2):151-153. Epub 2018 Jan 18.

Cancer Institute Gustave Roussy, University Paris-Sud, 98400 Villejuif/Paris-Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30016-0DOI Listing
February 2018

Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy.

J Natl Cancer Inst 2018 01;110(1)

European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France; The Christie NHS Foundation Trust, Manchester, UK; University of Pittsburgh Cancer Institute and School of Medicine, Pittsburgh, PA; Mayo Clinic Rochester, Rochester, MN; University of Tubingen, Tubingen, Germany; University of Edinburgh, Western General Hospital, Edinburgh, UK; Bristol-Myers Squibb, Wallingford, CT; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK; Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK; Universitas Brawijaya, Malang, Indonesia; IDDI, Louvain-la-Neuve, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djx133DOI Listing
January 2018

Development and evaluation of an isolated limb infusion model for investigation of drug delivery kinetics to solid tumors by thermosensitive liposomes and hyperthermia.

J Control Release 2018 01 18;270:282-289. Epub 2017 Dec 18.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2017.12.012DOI Listing
January 2018

Pre-SN Ultrasound-FNAC can be Sensitive for Lymph Node Metastases in Melanoma Patients if Performed with the Use of the Berlin Criteria.

Ann Surg Oncol 2017 12 20;24(Suppl 3):661-662. Epub 2017 Nov 20.

Institut de Cancérologie, Gustav Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-017-6230-7DOI Listing
December 2017

The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

Eur J Cancer 2017 11 29;86:101-105. Epub 2017 Sep 29.

University Hospital Zürich, Department of Dermatology, Zürich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.09.014DOI Listing
November 2017

Investigation of Particle Accumulation, Chemosensitivity and Thermosensitivity for Effective Solid Tumor Therapy Using Thermosensitive Liposomes and Hyperthermia.

Theranostics 2016 24;6(10):1717-31. Epub 2016 Jun 24.

1. Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus MC, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.14960DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955068PMC
October 2017

Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis.

Eur J Cancer 2017 09 7;82:171-183. Epub 2017 Jul 7.

Cancer Research UK Clinical Trials Unit, College of Medical and Dental Sciences, Robert Aitken Institute, University of Birmingham, Birmingham, B15 2TT, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.06.006DOI Listing
September 2017

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

Eur J Cancer 2017 08 15;81:116-129. Epub 2017 Jun 15.

Research Branch, Sidra Medical and Research Centre, Doha, Qatar. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.01.035DOI Listing
August 2017

Comparing the therapeutic potential of thermosensitive liposomes and hyperthermia in two distinct subtypes of breast cancer.

J Control Release 2017 07 4;258:34-42. Epub 2017 May 4.

Department of Surgery, Erasmus MC, 's-Gravendijkwal 230, PO Box 2040, 3000 CA Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2017.05.005DOI Listing
July 2017

Ipilimumab Adjuvant Therapy in Melanoma.

N Engl J Med 2017 01;376(4):399

European Institute of Oncology, Milan, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1615564DOI Listing
January 2017

Adjuvant ipilimumab in stage III melanoma: New landscape, new questions.

Eur J Cancer 2016 12 4;69:39-42. Epub 2016 Nov 4.

Gustave Roussy Cancer Campus Grand Paris, Villejuif, France; Universite Paris-Sud, Kremlin-Bicêtre, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.10.009DOI Listing
December 2016

A systematic review examining factors influencing health related quality of life among melanoma cancer survivors.

Eur J Cancer 2016 12 11;69:189-198. Epub 2016 Nov 11.

European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.10.008DOI Listing
December 2016

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

N Engl J Med 2016 11 7;375(19):1845-1855. Epub 2016 Oct 7.

From Gustave Roussy Cancer Campus Grand Paris, Villejuif (A.M.M.E., C.R.), Aix-Marseille University, Hôpital de La Timone, Marseille (J.-J.G.), Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris (C.L.), University Lille, INSERM Unité-1189, Centre Hospitalier Universitaire (CHU) Lille, Service de Dermatologie, Lille (L.M.), and CHU Lyon, Lyon (L.T.) - all in France; the Oncology Institute of Veneto-Istituto di Ricovero e Cura a Carattere Scientifico, Padua (V.C.-S.), Istituto Nazionale Tumori Fondazione G. Pascale, Naples (P.A.A.), Istituti Fisioterapici Ospitalieri, Rome (V.F.), University Hospital of Siena, Istituto Toscano Tumori, Siena (M.M.), and the European Institute of Oncology, Milan (A.T.) - all in Italy; University of Zurich Hospital, Zurich, Switzerland (R.D.); Memorial Sloan Kettering Cancer Center, New York (J.D.W.); Aarhus University Hospital, Aarhus (H.S.), and Odense University Hospital, Odense (L.B.) - both in Denmark; the Angeles Clinic and Research Institute, Los Angeles (O.H.); Oncology Specialists, Park Ridge, IL (J.M.R.); Cross Cancer Institute, Edmonton, AB, Canada (M.S.); H. Lee Moffitt Cancer Center, Tampa, FL (J.S.W.); Broomfield Hospital, Chelmsford, United Kingdom (S.T.); Universitätsklinikum Schleswig-Holstein, Kiel (A.H.), and University Hospital Heidelberg, Heidelberg (J.C.H.) - both in Germany; Dana-Farber Cancer Institute, Boston (F.S.H.); Bristol-Myers Squibb, Princeton, NJ (C.T., V.P.); and the European Organization for Research and Treatment of Cancer, Brussels (G.S., S.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648545PMC
November 2016

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.

Eur Urol 2016 10 23;70(4):623-632. Epub 2015 Dec 23.

INSERM (Institut National de la Santé et de la Recherche Médicale) UMR1186, Laboratory Integrative Tumor Immunology and Genetic Oncology, Villejuif, France; INSERM, Gustave Roussy, Univ. Paris-Sud, Université Paris-Saclay, Villejuif, F-94805, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2015.11.029DOI Listing
October 2016

Tissue inhibitor of metalloproteinase-3 (TIMP3) expression decreases during melanoma progression and inhibits melanoma cell migration.

Eur J Cancer 2016 10 11;66:34-46. Epub 2016 Aug 11.

Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands; Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.06.020DOI Listing
October 2016

Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.

Melanoma Res 2016 08;26(4):367-76

aDepartment of Oncology, Odense University Hospital, Odense C bThe Finsen Laboratory, Rigshospitalet, and Biotech Research and Innovation Centre, University of Copenhagen, København Departments of cOncology dMedicine ePathology, Herlev University Hospital, Herlev fAarhus University Hospital, Aarhus, Denmark gDepartment of Surgical Oncology, Erasmus University Medical Center-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands hKarolinska Institute, Stockholm, Sweden iEORTC Headquarters, Brussels, Belgium jGustave Roussy Cancer Institute, Villejuif, France.

View Article

Download full-text PDF

Source
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/CMR.0000000000000237DOI Listing
August 2016

Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades.

Oncoimmunology 2016 12;5(10):e1219826. Epub 2016 Aug 12.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center , Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/2162402X.2016.1219826DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087299PMC
August 2016

Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity.

Melanoma Res 2016 06;26(3):267-71

aDepartment of Dermatology, Venerology and Allergology, Charité - University of Medicine Berlin, Berlin bDepartment of Dermatology, Harz Skin Cancer Center, Quedlinburg, Germany cDepartment of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam dDepartment of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands eGustav Roussy, Institute of Oncology, Villejuif/Paris-Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000223DOI Listing
June 2016

Pharmacokinetics, Tissue Distribution and Therapeutic Effect of Cationic Thermosensitive Liposomal Doxorubicin Upon Mild Hyperthermia.

Pharm Res 2016 Mar 30;33(3):627-38. Epub 2015 Oct 30.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center, POBox 1738, 3000, DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11095-015-1815-y
Publisher Site
http://dx.doi.org/10.1007/s11095-015-1815-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744262PMC
March 2016

In depth study on thermosensitive liposomes: Optimizing formulations for tumor specific therapy and in vitro to in vivo relations.

Biomaterials 2016 Mar 22;82:138-50. Epub 2015 Dec 22.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Centre, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2015.12.023DOI Listing
March 2016

Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.

Cancer Res 2016 Mar 29;76(6):1476-84. Epub 2016 Jan 29.

Département de médecine oncologique, Gustave Roussy, Villejuif, France. INSERM, U981, Villejuif, France. Faculté de Médecine, Université Paris-Sud, Le Kremlin Bicetre, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2900-TDOI Listing
March 2016

Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive Liposomes.

Pharm Res 2015 Dec 23;32(12):3862-76. Epub 2015 Jul 23.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology Department of Surgery, Erasmus MC Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-015-1746-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4628091PMC
December 2015

Precision cancer medicine: the future is now, only better.

Am Soc Clin Oncol Educ Book 2014 :61-9

From the MD Anderson Cancer Center, Houston, TX; Institute Gustave-Roussy, Paris, France; American Society of Clinical Oncology, Alexandria, VA.

View Article

Download full-text PDF

Source
http://meetinglibrary.asco.org/content/114000061-144
Publisher Site
http://dx.doi.org/10.14694/EdBook_AM.2014.34.61DOI Listing
November 2015

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.

J Clin Oncol 2015 Nov 24;33(32):3817-25. Epub 2015 Aug 24.

Maria Schwaederle, Melissa Zhao, and Razelle Kurzrock, Center for Personalized Cancer Therapy, University of California, San Diego, Moores Cancer Center, La Jolla, CA; J. Jack Lee and John Mendelsohn, The University of Texas MD Anderson Cancer Center, Houston, TX; Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Alexander M. Eggermont and Vladimir Lazar, Institut Gustave Roussy, University Paris-Sud; and Alexander M. Eggermont, Richard L. Schilsky, John Mendelsohn, Vladimir Lazar, and Razelle Kurzrock, Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/32/3817.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.5997
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.5997DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737863PMC
November 2015

Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.

J Natl Cancer Inst 2015 Nov 15;107(11). Epub 2015 Sep 15.

Department of Clinical Medicine, Hemocentro da Unicamp, University of Campinas, Sao Paulo, Brazil (DLFJ); Department of Clinical Oncology, Hospital Sirio Libanes, Sao Paulo, Brazil (DLFJ); Center for Personalized Cancer Therapy and Division of Hematology and Oncology, University of California, San Diego, CA (MS, RK); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX (CW, JJL); Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX (DSH); Department of Functional Genomics, Institut Gustave Roussy, University Paris-Sud, Villejuif, France (AME, VL); Worldwide Innovative Network in Personalized Cancer Medicine, Villejuif, France (AME, RLS, JM, VL, RK); American Society of Clinical Oncology, Alexandria, VA (RLS); The University of Texas MD Anderson Cancer Center, Houston, TX (JM).

View Article

Download full-text PDF

Source
http://jnci.oxfordjournals.org/content/107/11/djv253.full.pd
Web Search
http://jnci.oxfordjournals.org/content/108/3/djv430.full.pdf
Web Search
http://jnci.oxfordjournals.org/lookup/doi/10.1093/jnci/djv25
Publisher Site
http://dx.doi.org/10.1093/jnci/djv253DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4857149PMC
November 2015

Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.

Melanoma Res 2015 Oct;25(5):427-31

aDepartment of Surgical Oncology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands bGustave Roussy Cancer Campus Grand Paris, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000177DOI Listing
October 2015

Who benefits most from adjuvant interferon treatment for melanoma?

Am J Ther 2015 Jan-Feb;22(1):54-60

1First Department of Medicine, Athens University Medical School, Athens, Greece; 2Division of Medical Oncology, Baskent University School of Medicine, Adana, Turkey; 3Unit of Medical Oncology and Innovative Therapy, Istituto Nazionale Tumori Fondazione "G. Pascale," Naples, Italy; 4Department of Biotherapy, Blokhin Cancer Center, Moscow, Russia; 5Department of Dermatology, Medical University of Vienna, Vienna, Austria; 6Department of Dermatology, Institute Gustave Roussy, Villejuif Cedex, France; 7Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel; 8Department of Dermatologie, University of Kiel, Kiel, Germany; and 9Oncology Service, Hospital La Paz, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e31829e883dDOI Listing
September 2015

Side effects and toxicities of targeted therapies in stage IV melanoma.

Am J Ther 2015 Jan-Feb;22(1):44-53

1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy; 2Odense University Hospital, Odense, Denmark; 3Newcastle University, Newcastle, Australia; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Institut Gustave Roussy, Villejuif, France; 6University of Kiel, Kiel, Germany; 7Hospital La Paz, Madrid, Spain; and 8Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e3182a39858DOI Listing
September 2015

Treatment algorithms in stage IV melanoma.

Am J Ther 2015 Jan-Feb;22(1):61-7

1Service of Oncology, Hospital La Paz, Madrid, Spain; 2Department of Dermatology, Hopital Ste Marguerite, Marseille, France; 3Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland; 4Department of Sarcoma and Melanoma, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 5Department of Dermatology (CR), and General Director (AE), Institute Gustave Roussy, Villejuif Cedex, France; 6First Department of Medicine, University of Athens Medical School, Athens, Greece; 7Department of Oncology, Westmead Hospital and Melanoma Institute Australia, University of Sydney, Sydney, Australia; 8Service of Oncology, Clinica Universitaria de Navarra, Pamplona, Spain; 9Department of Dermatology, University of Kiel, Kiel, Germany; and 10Department of Dermatology, University Hospital Essen, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e31829e885cDOI Listing
September 2015

C8-glycosphingolipids preferentially insert into tumor cell membranes and promote chemotherapeutic drug uptake.

Biochim Biophys Acta 2015 Aug 24;1848(8):1656-70. Epub 2015 Apr 24.

Unidad de Biofísica (CSIC, UPV/EHU), P.O. Box 644, 48080 Bilbao, Spain; Departamento de Bioquímica, Universidad del País Vasco, P.O. Box 644, 48080 Bilbao, Spain; IKERBASQUE, Basque Foundation for Science, 48011 Bilbao, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbamem.2015.04.011DOI Listing
August 2015

Plasma membrane targeting by short chain sphingolipids inserted in liposomes improves anti-tumor activity of mitoxantrone in an orthotopic breast carcinoma xenograft model.

Eur J Pharm Biopharm 2015 Aug 14;94:207-19. Epub 2015 May 14.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam 3000 CA, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpb.2015.05.003DOI Listing
August 2015

Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.

Semin Oncol 2015 Jun 14;42(3):429-35. Epub 2015 Feb 14.

Gustave Roussy Cancer Campus Grand Paris and University Paris-Sud, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.02.010DOI Listing
June 2015

A ring barrier-based migration assay to assess cell migration in vitro.

Nat Protoc 2015 Jun 21;10(6):904-15. Epub 2015 May 21.

Laboratory of Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center, Rotterdam, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nprot.2015.056DOI Listing
June 2015

Sex differences in melanoma survival are not related to mitotic rate of the primary tumor.

Ann Surg Oncol 2015 May 19;22(5):1598-603. Epub 2014 Nov 19.

Department of Public Health, Erasmus Medical Center, Rotterdam, The Netherlands,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-014-4166-8DOI Listing
May 2015

Short-chain glycoceramides promote intracellular mitoxantrone delivery from novel nanoliposomes into breast cancer cells.

Pharm Res 2015 Apr 16;32(4):1354-67. Epub 2014 Oct 16.

Section Surgical Oncology, Department of Surgery, Laboratory Experimental Surgical Oncology, Room Ee151b, Erasmus MC, 3000CA, Rotterdam, PO Box 2040, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11095-014-1539-4DOI Listing
April 2015

Treatment modifications in tumour necrosis factor-α (TNF)-based isolated limb perfusion in patients with advanced extremity soft tissue sarcomas.

Eur J Cancer 2015 Feb 16;51(3):367-73. Epub 2014 Dec 16.

Dept. Surgical Oncology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.11.020DOI Listing
February 2015

Targeted and heat-triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes.

J Control Release 2014 Dec 29;195:37-48. Epub 2014 Aug 29.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2014.07.058DOI Listing
December 2014

Classification of current anticancer immunotherapies.

Oncotarget 2014 Dec;5(24):12472-508

Equipe 11 labellisée pas la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France. INSERM, U1138, Paris, France. Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France. Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France. Pôle de Biologie, Hôpital Européen Georges Pompidou (HEGP), AP-HP, Paris, France.

View Article

Download full-text PDF

Source
https://lirias.kuleuven.be/bitstream/123456789/502976/1/2998
Web Search
http://oncotarget.com/abstract/2998
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350348PMC
http://dx.doi.org/10.18632/oncotarget.2998DOI Listing
December 2014

Clinical cancer research: the past, present and the future.

Nat Rev Clin Oncol 2014 Nov 23;11(11):663-9. Epub 2014 Sep 23.

Radcliffe Department of Medicine, University of Oxford, Headley Way, Oxford OX3 9DU, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.153DOI Listing
November 2014

Cancer Core Europe: a consortium to address the cancer care-cancer research continuum challenge.

Eur J Cancer 2014 Nov 25;50(16):2745-6. Epub 2014 Sep 25.

National Center for Tumour Diseases (DKFZ-NCT), Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.07.025DOI Listing
November 2014

SLNB in melanoma-DFS a true and cost-effective benefit?

Nat Rev Clin Oncol 2014 Nov 14;11(11). Epub 2014 Oct 14.

Cancer Institute, Gustave Roussy Cancer Campus, Grand Paris, 114 rue Édouard Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.65-c3DOI Listing
November 2014

Ultrasound diagnosis of an atypical axillary lesion.

Melanoma Res 2014 Oct;24(5):517-21

aDepartment of Dermatology, Charité, Humboldt University of Berlin, Berlin bDepartment of Dermatology, University of Mainz, Mainz, Germany cDepartment of Surgical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands dInstitute Gustave Roussy Cancer Center, Villejuif, Paris Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0000000000000105DOI Listing
October 2014

Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients.

Eur J Cancer 2014 Sep 3;50(13):2280-8. Epub 2014 Jul 3.

Institut de Cancérologie Gustav Roussy, Paris-Sud/Villejuif, France; European Organization for Research and Treatment of Cancer (EORTC) Melanoma Group (MG), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2014.05.027DOI Listing
September 2014

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Nature 2014 Sep 27;513(7516):105-9. Epub 2014 Jul 27.

1] Inserm UMR981, Villejuif F-94805, France [2] Université Paris-Sud XI, Kremlin-Bicêtre F-94276, France [3] Gustave Roussy, Dermato-Oncology, Villejuif F-94805, France [4] Department of Surgical and Perioperative Sciences, Umeå University, Umeå SE-90187, Sweden (O.H.); CNRS UMR3348, Institut Curie, Orsay F-91405, France (S.V.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature13572DOI Listing
September 2014

Melanoma: MSLT-1--SNB is a biomarker, not a therapeutic intervention.

Nat Rev Clin Oncol 2014 May 8;11(5):248-9. Epub 2014 Apr 8.

Cancer Institute, Gustave Roussy Cancer Campus, Grand Paris, 114 rue Édouard Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.64DOI Listing
May 2014

Melanoma: smart therapeutic strategies in immuno-oncology.

Nat Rev Clin Oncol 2014 Apr 4;11(4):181-2. Epub 2014 Mar 4.

Department of Dermatology, Gustave Roussy Cancer Campus, Grand Paris, 114 rue Édouard Vaillant, 94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrclinonc.2014.36DOI Listing
April 2014

Cutaneous melanoma.

Lancet 2014 Mar 19;383(9919):816-27. Epub 2013 Sep 19.

Melanoma Unit and INSERM U981, Gustave Roussy Cancer Institute, Grand Paris, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(13)60802-8DOI Listing
March 2014

Metastatic melanoma to the liver: a contemporary and comprehensive review of surgical, systemic, and regional therapeutic options.

Cancer 2014 Mar 2;120(6):781-9. Epub 2013 Dec 2.

Department of Hematology/Oncology, St. Luke's University Health Network, Bethlehem, Pennsylvania.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.28480
Publisher Site
http://dx.doi.org/10.1002/cncr.28480DOI Listing
March 2014

Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration.

Angiogenesis 2014 Jan 25;17(1):163-77. Epub 2013 Sep 25.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center, Room Ee 0104a, PO Box 1738, 3000 DR, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10456-013-9385
Web Search
http://link.springer.com/10.1007/s10456-013-9385-2
Publisher Site
http://dx.doi.org/10.1007/s10456-013-9385-2DOI Listing
January 2014

A novel two-step mild hyperthermia for advanced liposomal chemotherapy.

J Control Release 2014 Jan 22;174:202-8. Epub 2013 Nov 22.

Laboratory Experimental Surgical Oncology, Section Surgical Oncology, Department of Surgery, Erasmus Medical Center, 3000 CA Rotterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://a-haeri.com/wp-content/uploads/2015/07/JCR2014.pdf
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S016836591300901
Publisher Site
http://dx.doi.org/10.1016/j.jconrel.2013.11.012DOI Listing
January 2014

Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial.

J Clin Oncol 2013 Oct 9;31(30):3831-7. Epub 2013 Sep 9.

Alexander M.M. Eggermont, Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, and Université Paris-Sud, Kremlin Bicêtre, Paris, France; Stefan Suciu, Larissa Polders, and Michel Praet, European Organisation for Research and Treatment of Cancer, Brussels, Belgium; Piotr Rutkowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Jeremy Marsden, University Hospital Birmingham, Birmingham; Philippa Corrie, Addenbrookes Hospital, Cambridge; Poulam M. Patel, University of Nottingham, Nottingham; Neville Davidson, Broomfield Hospital, Broomfield, United Kingdom; Mario Santinami, Istituto Nazionale dei Tumori, Milan; Paolo A. Ascierto, Istituto Nazionale Tumori Fondazione Pascale, Napoli; Lorenzo Borgognoni, Istituto Tumori Toscano, S. Maria Annunziata Hospital, Florence; Maria Grazia Bernengo, University Hospital Turin, Turin, Italy; Steinar Aamdal, Oslo University Hospital and Radium Hospital, Oslo, Norway; Wim H. Kruit, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands; Lars Bastholt, Odense University Hospital, Odense, Denmark; and Alan Spatz, McGill University and Lady Davis Institute for Medical Research, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.47.9303DOI Listing
October 2013

Immunotherapy and the concept of a clinical cure.

Eur J Cancer 2013 Sep 25;49(14):2965-7. Epub 2013 Jul 25.

Institut Gustave Roussy, F-94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.06.019DOI Listing
September 2013

Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.

Eur J Cancer 2013 Sep 29;49(14):2968-71. Epub 2013 Jul 29.

Gustave Roussy Comprehensive Cancer Center, 114 Rue Edouard Vaillant, 94800 Villejuif/Paris-Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.07.001DOI Listing
September 2013

Adjuvant therapy for high-risk melanoma.

EJC Suppl 2013 Sep;11(2):106-8

Gustave Roussy Campus Cancer, University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcsup.2013.07.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041312PMC
September 2013